A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Meloxicam (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Iroko Pharmaceuticals
  • Most Recent Events

    • 23 Jun 2016 Results published in an Iroko Pharmaceuticals media release.
    • 14 May 2016 Results assessing rescue medication use (N=403) were presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 12 May 2016 Results published in the Iroko Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top